BeOne Medicines

BeOne Medicines

ONC· Manufacturing· Fiscal year ends in December

CEO pay in FY2024Stock +2.4% in FY2024

John V. Oyler is the CEO of BeOne Medicines and was paid $20.8M in FY2024 (Dec), up 10%.

Pay$100 in the stock at the end of FY20 → $71
CEO pay is from each BeOne Medicines proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1John V. OylerFY2024
  2. 2Dr. Lai WangFY2025
  3. 3Dr. Xiaobin WuFY2025
  4. 4Aaron RosenbergFY2025
  5. 5Chan LeeFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

BeOne Medicines paid its 4 named executives $41.8M in total in FY2025 (Dec).

Name
Dr. Lai WangPresident, Global Head of Research and Development
Dr. Xiaobin WuPresident and Chief Operating Officer
Aaron RosenbergChief Financial OfficerNot disclosed
Chan LeeSenior Vice President, General Counsel and Corporate Secretary
John V. OylerCo-Founder, Chairman and Chief Executive OfficerNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers13

See all

The FY2025 (Dec) proxy of BeOne Medicines names 13 peer companies for pay. Pay versus performance data of BeOne Medicines for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Activity

Filings6

See all
Proxy statementDEF 14AApr 28, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 7, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AApr 26, 2024FY2023
Annual report10-KFeb 26, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data